Growth Hormone Deficiency Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA

The Key Growth Hormone Deficiency Companies in the market include - Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others.

The Growth Hormone Deficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Growth Hormone Deficiency market dynamics.

DelveInsight's "Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Growth Hormone Deficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Growth Hormone Deficiency Market Forecast [https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Growth Hormone Deficiency Market Report:

*
In 2023, the Growth Hormone Deficiency market across the 7MM was estimated to be worth around USD 1.4 billion. Between 2025 and 2034, the market is expected to expand at a compound annual growth rate (CAGR) of 5.7%.

*
In 2023, the Growth Hormone Deficiency market in the United States was valued at around USD 873.4 million and is expected to grow further with the introduction of upcoming therapies.

*
In 2023, the combined market size of the EU4 and the UK was estimated at around USD 370.2 million, accounting for nearly 27% of the total revenue across the 7MM.

*
In 2023, Germany led the Growth Hormone Deficiency market within the EU4 and the UK, with revenue of approximately USD 96.5 million. The UK came next with around USD 86.2 million, followed by France at roughly USD 82.0 million.

*
In 2023, Japan's total market size for Growth Hormone Deficiency was estimated at around USD 137.0 million, with expectations of growth throughout the forecast period (2025-2034).

*
Projections indicate that LUM-201 is anticipated to generate around USD 131.1 million in revenue across the 7MM by 2034.

*
DelveInsight estimates that in 2023, there were around 206,000 total prevalent cases of Growth Hormone Deficiency across the 7MM, with approximately 165,000 of those being diagnosed. Among the diagnosed cases, the United States accounted for about 42.5%, while the combined total for EU4 and the UK was close to 41.7%, and Japan comprised 15.8%.

*
Currently, the Growth Hormone Deficiency treatment landscape includes therapies such as somatotropin, SOGROYA, SKYTROFA/TRANSCON hGH, NGENLA, GROWJECT, and others available in the market.

*
According to DelveInsight, the prevalence of Growth Hormone Deficiency in the 7MM was approximately 206,000 in 2023. This figure is expected to rise at a CAGR of 0.4%, reaching greater levels by 2034.

*
DelveInsight estimates that approximately 165,000 diagnosed cases of Growth Hormone Deficiency were reported across the 7MM in 2023. This number is anticipated to grow at a CAGR of 0.4% throughout the forecast period (2020-2034).

*
In 2023, the United States represented roughly 51% of the diagnosed prevalent pediatric Growth Hormone Deficiency cases across the 7MM, while EU4 and the UK contributed close to 36%, and Japan accounted for about 13%.

*
In 2023, the United States made up about 40% of the diagnosed prevalent adult Growth Hormone Deficiency cases in the 7MM, while EU4 and the UK comprised nearly 43%, and Japan contributed approximately 17%.

*
In 2023, the United States reported around 49,000 cases of Growth Hormone Deficiency in males and 21,000 in females, with these figures projected to increase by 2034.

*
In 2023, approximately 42,000 male and 26,000 female cases of Growth Hormone Deficiency were reported in the EU4 and the UK, with these numbers anticipated to grow by 2034.

*
Key Growth Hormone Deficiency Companies: Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others

*
Key Growth Hormone Deficiency Therapies: SOGROYA (somapacitan-beco), SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd), LUM-201 (ibutamoren), SCO-240, and others

*
The Growth Hormone Deficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Growth Hormone Deficiency pipeline products will significantly revolutionize the Growth Hormone Deficiency market dynamics.

Growth Hormone Deficiency Overview

Growth Hormone Deficiency (GHD) is a medical condition in which the body doesn't produce enough growth hormone, a key hormone responsible for growth, cell repair, and metabolism. It can occur in both children and adults. In children, GHD leads to slowed growth and short stature, while in adults, it may cause fatigue, reduced muscle mass, increased fat, and poor bone density. Causes can include genetic disorders, brain injuries, or tumors. Treatment typically involves daily injections of synthetic growth hormone to restore normal growth and metabolic function.

Request a sample for the Growth Hormone Deficiency Market Report:

https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market [https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Growth Hormone Deficiency Epidemiology

The Growth Hormone Deficiency epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Growth Hormone Deficiency Epidemiology Segmentation:

The Growth Hormone Deficiency market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Growth Hormone Deficiency

*
Prevalent Cases of Growth Hormone Deficiency by severity

*
Gender-specific Prevalence of Growth Hormone Deficiency

*
Diagnosed Cases of Episodic and Chronic Growth Hormone Deficiency

Download the report to understand which factors are driving Growth Hormone Deficiency epidemiology trends @ Growth Hormone Deficiency Epidemiological Insights [https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Growth Hormone Deficiency Market

The dynamics of the Growth Hormone Deficiency market are anticipated to change in the coming years owing to the expected launch of emerging therapies, and others during the forecast period 2020-2034.

Growth Hormone Deficiency Therapies and Companies

*
Novo Nordisk: SOGROYA (somapacitan-beco)

*
Ascendis Pharma: SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd)

*
Double Point Ventures (Lumos Pharma): LUM-201 (ibutamoren)

*
SCOHIA PHARMA: SCO-240

To know more about Growth Hormone Deficiency treatment, visit @ Growth Hormone Deficiency Medications [https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Growth Hormone Deficiency Market Strengths

*
Various approved therapies are available in the market for this condition which can help in successfully treating PGHD.

*
The emerging pipeline has some very potential treatments for PGHD.

Growth Hormone Deficiency Market Opportunities

*
Since the emerging and approved treatments mainly comprise of long-acting hGH, this is a major opportunity for companies to develop novel drugs with innovative mechanism of action for PGHD which will give them an edge in the current market.

Scope of the Growth Hormone Deficiency Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Growth Hormone Deficiency Companies: Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others

*
Key Growth Hormone Deficiency Therapies: SOGROYA (somapacitan-beco), SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd), LUM-201 (ibutamoren), SCO-240, and others

*
Therapeutic Assessment: Growth Hormone Deficiency current marketed and Growth Hormone Deficiency emerging therapies

*
Growth Hormone Deficiency Market Dynamics: Growth Hormone Deficiency market drivers and barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Growth Hormone Deficiency Unmet Needs, KOL's views, Analyst's views, Growth Hormone Deficiency Market Access and Reimbursement

Discover more about therapies set to grab major Growth Hormone Deficiency market share @ Growth Hormone Deficiency Treatment Landscape [https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Growth Hormone Deficiency Market Report Introduction

2. Executive Summary for Growth Hormone Deficiency

3. SWOT analysis of Growth Hormone Deficiency

4. Growth Hormone Deficiency Patient Share (%) Overview at a Glance

5. Growth Hormone Deficiency Market Overview at a Glance

6. Growth Hormone Deficiency Disease Background and Overview

7. Growth Hormone Deficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Growth Hormone Deficiency

9. Growth Hormone Deficiency Current Treatment and Medical Practices

10. Growth Hormone Deficiency Unmet Needs

11. Growth Hormone Deficiency Emerging Therapies

12. Growth Hormone Deficiency Market Outlook

13. Country-Wise Growth Hormone Deficiency Market Analysis (2020-2034)

14. Growth Hormone Deficiency Market Access and Reimbursement of Therapies

15. Growth Hormone Deficiency Market drivers

16. Growth Hormone Deficiency Market barriers

17. Growth Hormone Deficiency Appendix

18. Growth Hormone Deficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Garurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=growth-hormone-deficiency-market-predicted-to-see-upsurge-through-2034-highlights-delveinsight-novo-nordisk-ascendis-pharma-double-point-ventures-lumos-pharma-scohia-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.